CEO Lawrence Klein describes advances in antibody engineering Oruka is leveraing to make improved IL-23 and IL-17 inhibitors.

Sek Kathiresan describes what Verve believes caused elevated liver enzymes and thrombocytopenia in a PCSK9 gene editing trial.

Thomas Shrader shares his thoughts on biotech and comments on companies he covers.

Peter Maag describes how Kyverna has been focused on this area for five years.

Paul Hastings describes why Nkarta believes NK based therapies are uniquely fit for this area.

John Scarlett shares his take on imetelstat's clinical utility, potential commercial dynamics, the IP situation, and more.

BiotechTV visited the Freemont, CA headquarters of Ultima Genomics and spoke with CEO Gilad Almogy about their approach.

Andy Hsieh gives his take on the radiopharmaceutical space, Viking’s obesity data, Pyxis Oncology, Cardiff Oncology, Fibrogen.

Founder Mark McKenna describes the unmet need that exists in the I&I space.

Alexandria Forbes describes the investments MeiraGTx has made in manufacturing and how it is helped progress various programs.

Evan Seigerman breaks down which companies and technologies are at the forefront of the the GLP space.

Ali Gorman will be covering biotech news and cool research in the greater Philadelphia area for BiotechTV.

Matt Phipps covers Janux, NewAmsterdam, Jasper, Autolus, Incyte, Merus, and Amgen.

Laura Chico gives her take on the state of biotech and discusses Denali, Praxis, Viridian, Apellis, PepGen, and Edgewise.

David Campbell explains how Janux has used masking technology to improve the profile T-cell engagers in solid tumors.

Fabrice Chouraqui describes Cellarity's platform and how it is being put to use for indications such as sickle cell disease and MASH.

Chris Varma describes why hitting KRAS G12C in both its on and off state could be an improvement over existing medicines.

CEO Michael Davidson describes how Obicetrapib, which was reacquired from Amgen, is designed to produce more LDL lowering than others.